Alterity Therapeutics Limited

NasdaqCM:ATHE Voorraadrapport

Marktkapitalisatie: US$10.5m

Alterity Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

Alterity Therapeutics's earnings are forecast to decline at 2.7% per annum while its annual revenue is expected to grow at 25% per year.

Belangrijke informatie

-2.7%

Groei van de winst

n/a

Groei van de winst per aandeel

Biotechs winstgroei27.1%
Inkomstengroei25.0%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Low

Laatst bijgewerkt29 Aug 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Alterity launches phase 2 study of ATH434 for multiple system atrophy in UK

Aug 25

Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy

Jul 06

Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone Technology

Sep 16

Alterity Therapeutics names Dr. David Stamler as CEO

Jan 07

Alterity and UniQuest partner to reverse bacterial resistance to antibiotics

Dec 21

Alterity Therapeutics nabs US patent for compounds for neurodegenerative disorders

Nov 16

Winst- en omzetgroeiprognoses

NasdaqCM:ATHE - Toekomstschattingen van analisten en financiële gegevens uit het verleden (AUD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
6/30/20267-20N/A-201
6/30/20259-18-8-181
6/30/20244-19-13-13N/A
3/31/20244-16-14-14N/A
12/31/20233-12-15-15N/A
9/30/20234-13-17-17N/A
6/30/20234-14-20-20N/A
3/31/20235-14-17-17N/A
12/31/20225-14-14-14N/A
9/30/20225-14-13-13N/A
6/30/20225-13-12-12N/A
3/31/20225-13-16-16N/A
12/31/20215-13-19-19N/A
9/30/20215-14-18-18N/A
6/30/20214-15-17-17N/A
3/31/20212-16-16-16N/A
12/31/20200-16-14-14N/A
9/30/20200-15-12-12N/A
6/30/2020N/A-13-9-9N/A
3/31/20202-13-9-9N/A
12/31/20194-13-9-9N/A
9/30/20195-12-12-12N/A
6/30/20195-12-14-14N/A
3/31/20195-11-13-13N/A
12/31/20184-10-12-12N/A
9/30/20184-9-9-9N/A
6/30/20183-8-6-6N/A
3/31/20183-8N/A-6N/A
12/31/20173-8N/A-6N/A
9/30/20173-8N/A-6N/A
6/30/20173-8N/A-6N/A
3/31/20174-8N/A-3N/A
12/31/20164-9N/A-1N/A
9/30/20164-8N/A-4N/A
6/30/20165-8N/A-7N/A
3/31/20165-8N/A-9N/A
12/31/20156-7N/A-10N/A
9/30/20156-7N/A-10N/A
6/30/20156-6N/A-11N/A
3/31/20158-6N/A-13N/A
12/31/201410-7N/A-15N/A
9/30/20149-10N/A-14N/A
6/30/20148-13N/A-14N/A
3/31/20146-12N/A-12N/A
12/31/20134-11N/A-11N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: ATHE is forecast to remain unprofitable over the next 3 years.

Winst versus markt: ATHE is forecast to remain unprofitable over the next 3 years.

Hoge groeiwinsten: ATHE is forecast to remain unprofitable over the next 3 years.

Omzet versus markt: ATHE's revenue (25% per year) is forecast to grow faster than the US market (8.9% per year).

Hoge groei-inkomsten: ATHE's revenue (25% per year) is forecast to grow faster than 20% per year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if ATHE's Return on Equity is forecast to be high in 3 years time


Ontdek groeibedrijven